Pfizer Wins on Toviaz Patents in Patent Office Proceedings

The U.S. Patent Office upheld five patents on Pfizer Inc.'s overactive bladder treatment Toviaz, in a win for Pfizer and patent owner UCB Pharma GmbH.

The U.S. Patent Office’s Patent Trial and Appeal Board July 19 found five patents covering Toviaz (fesoterodine fumarate) were valid in a series of final written decisions. These, coupled with prior federal district court decisions upholding the patents, mean that no generic versions of Toviaz can enter the market until the patents expire in July 2022.

But because the patent holder has the discretion to allow generics to enter the market before then, the timing ...